Cresco Labs (CRLBF) to Release Quarterly Earnings on Thursday

Cresco Labs (OTCMKTS:CRLBF) is expected to be announcing its results before the market opens on Thursday, March 5th. Analysts expect the company to announce earnings of ($0.02) per share and revenue of $160.8740 million for the quarter.

Cresco Labs Price Performance

Shares of OTCMKTS CRLBF traded down $0.02 during trading on Monday, reaching $0.97. The company had a trading volume of 339,980 shares, compared to its average volume of 837,309. Cresco Labs has a 52 week low of $0.43 and a 52 week high of $2.30. The company has a debt-to-equity ratio of 1.28, a quick ratio of 1.54 and a current ratio of 2.49. The business’s 50 day moving average price is $1.14 and its 200-day moving average price is $1.14. The stock has a market cap of $346.89 million, a PE ratio of -6.47 and a beta of 1.47.

Analyst Ratings Changes

Several research analysts have weighed in on the company. ATB Cormark Capital Markets raised Cresco Labs to an “outperform” rating in a research report on Tuesday, December 2nd. Zacks Research cut shares of Cresco Labs from a “hold” rating to a “strong sell” rating in a report on Friday, February 6th. One equities research analyst has rated the stock with a Strong Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy”.

Cresco Labs Company Profile

Cresco Labs is a vertically integrated, multi-state cannabis operator in the United States. The company engages in the cultivation, manufacturing and distribution of a broad range of cannabis products, including flower, pre-rolled joints, concentrates, vaporizers, edibles and tinctures. Cresco Labs’ operations span cultivation facilities, processing laboratories and a network of wholesale distribution centers that supply licensed dispensaries and retail outlets across key cannabis markets.

The company’s product portfolio is organized under several branded platforms, such as MÜV, Reserve and High Supply, each designed to address different segments of the adult-use and medical cannabis markets.